Monoclonal gammopathy of undetermined significance

New England Journal of Medicine

Volumn 355, Issue 26, 2006, Pages 2765-2770

  Bladé, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; AMYLOIDOSIS; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); DISEASE COURSE; FOLLOW UP; HUMAN; LABORATORY DIAGNOSIS; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN ELECTROPHORESIS; RISK ASSESSMENT; WALDENSTROEM MACROGLOBULINEMIA; BLOOD; DIFFERENTIAL DIAGNOSIS; MIDDLE AGED; PLASMA CELL; REVIEW;

AMYLOIDOSIS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; MULTIPLE MYELOMA; PLASMA CELLS; WALDENSTROM MACROGLOBULINEMIA;

EID: 33845914364     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp052790     Document Type: Article

References (31)

1. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978;64:814-26.
2. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
3. Waldenström J. Studies on conditions associated with disturbed gamma globulin formation (gammopathies). Harvey Lect 1960-1961;56:211-31.
4. Axelsson U. A 20-year follow-up study of 64 subjects with M-components. Acta Med Scand 1986;219:519-22.
5. Kyle RA. 'Benign' monoclonal gammopathy: a misnomer? JAMA 1984;251:1849-54.
6. Idem. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993;68:26-36.
7. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ III. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004;79:859-66.
8. Bladé J. On the "significance" of monoclonal gammopathy of undetermined significance. Mayo Clin Proc 2004;79:855-6.
9. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-9.
10. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
11. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904-6.
12. Bergsagel PL, Kuehl WM. The molecular biology of multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma: biology and management. 3rd ed. Philadelphia: Saunders, 2004:35-58.
13. Fonseca R. Cytogenetics in multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma: biology and management. 3rd ed. Philadelphia: Saunders, 2004:67-81.
14. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.
15. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
16. Hideshima T, Chauhan D, Anderson KC. Cytokines, cytokine receptors, and signal transduction in human multiple myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Multiple myeloma: biology and management. 3rd ed. Philadelphia: Saunders, 2004:59-65.
17. Pasqualetti P, Festuccia V, Collacciani A, Casale R. The natural history of monoclonal gammopathy of undetermined significance: a 5- to 20-year follow-up of 263 cases. Acta Haematol 1997;97:174-9.
18. Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20:1625-34.
19. Montoto S, Bladé J, Montserrat E. Monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:2087-8.
20. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-7.
21. Kyle RA, Bladé J, Rajkumar SV. Monoclonal gammopathies of undetermined significance. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma: biology and management. 3rd ed. Philadelphia: Saunders, 2004:315-52.
22. Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996;87:912-8.
23. Bladé J, López-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992;81:391-4.
24. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HF. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001;86:1172-9.
25. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-44.
26. Bladé J, Fernández-Llamas P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in a series of 94 patients from a single institution. Arch Intern Med 1998;158:1889-93.
27. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57.
28. Magrangeas F, Nasser V, Avet-Loiseau H, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003;101:4998-5006.
29. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998;152:1655-65.
30. Rawstron AC, Fenton JAL, Gonzalez D, et al. Accurate prediction of outcome for IgG and IgA monoclonal gammopathy of unknown significance patients using flow cytometry. Haematologica 2005;90:Suppl 1:196. abstract.
31. Bladé J, Rosiñol L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treat Options Oncol 2006;7:237-45.